CVS Health reported a third-quarter beat and raised its full-year profit forecast, then watched the stock fall more than 12 percent in a single session. The culprit was not the numbers, adjusted earnings of $2.09 a share topped estimates by more than 20 percent and revenue rose 5.4 percent to $108.4 billion, but a surprise plan to cleave the company in two by the first half of 2028 with no standalone financials, no debt allocation, and no dividend math attached.
The split that wasn't teased
Management had never mentioned a breakup on previous calls. On Nov. 4 it laid out a structure that would create a health-services company, keeping the CVS Health name and housing Aetna, Caremark, Specialty, Oak Street and Signify under chief executive David Joyner, and a separate pharmacy company spanning 9,000 retail stores, mail order, MinuteClinic and virtual care, led by current group president Prem Shah. The transaction is intended to be tax-free for federal purposes. Final board approval is still pending.
Guidance that flatlines
The 2026 floor for adjusted earnings was lifted to at least $8.29 a share and operating cash flow guidance jumped to $15.5 billion from $11.5 billion. But the preliminary 2027 view calls for only $8.65, a 5 percent increase on the new floor, with pharmacy growth stuck in the low single digits. Analysts noted the split timeline leaves 18 months of exposure to Medicare rate changes, state legislation and a Tennessee lawsuit challenging pharmacy-benefit-manager ownership of pharmacies under the FAIR Rx Act.
Debt and dividend left blank
The company said separation costs would be shared but did not say how the balance sheet would be divided or how the $2.66 annual dividend would be split between the two future share classes. Without those details, the market treated the announcement as a defensive move against regulatory risk rather than a value-unlocking catalyst. Shares erased nearly all of the year-to-date advance.